Current Headlines

  1. Weill Cornell Medical College And Cellectis Announce Research Alliance Advancing Drug Discovery And The Translation Of Novel Immunotherapies In Leukemia
    6/2/2015

    Regulatory News: Weill Cornell Medical College and Cellectis have entered into a strategic translational research alliance to accelerate the development of a targeted immunotherapy for patients with acute myelogenous leukemia (AML), a deadly blood cancer

  2. Humanetics Corporation Granted FDA Clearance To Proceed With Cancer Treatment Study
    6/2/2015

    Minneapolis-based Humanetics Corporation (Humanetics) announced recently that its Investigational New Drug application for the proprietary compound BIO 300 has cleared U.S

  3. Rationally Designed Antifungal Compounds That Evade Resistance Reported In Nature Chemical Biology By Scientific Founder Of REVOLUTION Medicines
    6/1/2015

    REVOLUTION Medicines, Inc., a company focused on the discovery and development of innovative drugs derived from natural compounds, announced that progress in antimicrobial drug discovery was published recently in Nature Chemical Biology by the company’s academic founder and scientific advisory board chairman, Martin D. Burke, M.D., Ph.D., professor of chemistry, University of Illinois at Urbana-Champaign, and Early Career Scientist of the Howard Hughes Medical Institute

  4. Bruker Announces MALDI PharmaPulse, A Breakthrough High-Throughput Screening (HTS) Solution For Drug Discovery
    6/1/2015

    At the 63rd ASMS Conference on Mass Spectrometry and Allied Topics, Bruker recently announced a new high-throughput screening (HTS) solution designed to help pharmaceutical companies achieve high throughput, lower cost and higher specificity in drug discovery

  5. Pfizer’s RAPAMUNE (sirolimus) Becomes First FDA-Approved Treatment For Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease
    5/29/2015

    Pfizer Inc. announced recently that the U.S. Food and Drug Administration (FDA) has approved RAPAMUNE (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that affects the lungs, kidneys and the lymphatic system

  6. Beryllium Develops An MCL-1 Platform For Structure-Guided Drug Discovery In Collaboration With The Broad Institute
    5/27/2015

    Beryllium, a scientific research services company engaging in collaborations with commercial and academic partners, recently announced the development of an MCL-1 platform for structure-guided drug discovery

  7. Enanta Announces SVR12 Results Of 95% From AbbVie’s GIFT-1 Study In Non-Cirrhotic, Japanese Patients With Genotype 1b Hepatitis C Virus1
    5/26/2015

    Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced recently that new data from AbbVie’s phase 3 GIFT-I study, its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir, was presented at the Annual Meeting of the Japan Society of Hepatology in Kumamoto, Japan

  8. Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
    5/20/2015

    Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced recently that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to revusiran, an investigational RNAi therapeutic, for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis)

  9. Sarepta Therapeutics Announces Plans To Submit Rolling NDA For Eteplirsen Following Today’s Pre-NDA Meeting With The FDA
    5/19/2015

    Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics, recently announced that the Company held a pre-New Drug Application (NDA) meeting with the U.S

  10. Cyclenium Pharma Announces Drug Discovery Collaboration Agreement With Astellas Pharma
    5/12/2015

    Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the discovery and development of novel drug candidates based on proprietary macrocyclic chemistry, announced recently the signing of a drug discovery collaboration agreement with Astellas Pharma Inc., one of the world’s leading pharmaceutical discovery and development companies

Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.